TTUHSC Researchers Seek Novel Therapies for Chronic Pain
Ahmed receives NIH grant to study inhibitors that target peripheral neuropathic pain

To help spur the development of these therapies, the National Institute of Neurological Disorders and Stroke at the National Institutes of Health recently awarded a five-year, $1.94 million grant (“Identification of novel lead EphB1/2 tyrosine kinase inhibitors targeting peripheral neuropathic pain’) to Mahmoud Salama Ahmed, Ph.D., from the Department of Pharmaceutical Sciences at the Texas Tech University Health Sciences Center (TTUHSC) Jerry H. Hodge School of Pharmacy. The project team includes TTUHSC department colleagues Jenny Wilkerson, Ph.D., (co-investigator) and Heba Ewida, Ph.D., and graduate student Harrison Benson.
In previous behavioral research studies, Ahmed’s laboratory demonstrated significant reversal of thermal hyperalgesia (heightened sensitivity to heat or thermal stimuli) and mechanical allodynia (pain from a light touch, pressure or movement) induced by experimental nerve damage and a sciatic nerve constriction injury.
Ahmed’s previous research also revealed the synergism of three tetracycline family members: minocycline, chlortetracycline and demeclocycline.
“That study showed the competitive inhibitory profile of chlortetracycline and the catalytic binding domain of EphB1 tyrosine kinase (transmembrane proteins that mediate communication between cells),” Ahmed explained. “It also showed that the tetracycline combination reversed thermal hyperalgesia and mechanical allodynia in various pain models. However, the IC50 (the amount of a drug needed to inhibit a biological process by 50%) for this approach is in the low micromolar range, requiring a near maximal dose of all three antibiotics in combination.”
A micromolar is one-millionth (10^-6) of a mole, which is a unit of measurement representing a specific number of molecules or atoms. For some drugs, concentrations this high in humans are difficult to achieve without producing unwanted side effects.
While working at UT-Southwestern, Ahmed published a paper at the proceedings of the National Academy of Sciences resolving the crystal structure of one of the tetracyclines with the EphB1 tyrosine kinase domain. Ahmed said this kinase is integrated into the progression of peripheral neuropathic pain.
“However, it doesn't make sense that when we have a patient that's suffering from a peripheral neuropathic pain, we will give them this combo of the tetracyclines,” Ahmed said. “Because in the long-term, some of the adverse effects the patient might develop include antibiotic resistance. Also, the binding of the tetracyclines to the kinase domain was not optimum. Based on that, I started to look at the structure again, and I came up with new structures to achieve more potency and selectivity.”
Ahmed then began collaborating with Wilkerson at TTUHSC. First, Ahmed’s lab conducted the design phase, synthesized (collected) other evidence and findings from past research and conducted biochemical validation. When the project was set to scale up and conduct in vivo, pre-clinical models, they turned to Wilkerson’s lab.
Wilkerson has 17 years of experience researching the involvement of the immune system in various chronic neuropathic pain models. Using this expertise, Wilkerson’s laboratory will examine the potency of these new compounds to reverse or prevent behaviors associated with chronic neuropathic pain. Her laboratory will also determine if therapeutically relevant doses of these new compounds produce untoward behavioral side effects.
“This project holds a lot of promise because, for so many people, opioids and gabapentinoids are the main options to treat chronic pain, and we know that these drugs often do not work to adequately control pain,” Wilkerson said. “Additionally, this project is very exciting because we might be able to prevent chronic pain from developing.”
As they prepare for this latest study, Ahmed said they have 50 to 60 molecules in hand that exhibit better activity when compared to the tetracyclines used to target the EphB1 tyrosine kinase domain. Two of these molecules are undergoing preclinical evaluation for reversing all the key parameters for peripheral neuropathic pain, such as thermal hyperalgesia and mechanical allodynia.
“The EphB1/2 tyrosine kinase domain inhibitors have the potential to reverse the thermal hyperalgesia and the mechanical allodynia, and those stimuli are interrelated to peripheral neuropathic pain,” Ahmed said. “Our overall goal is to pharmacologically examine whether selective EphB1/2 tyrosine kinase inhibition is necessary and sufficient to reverse and/or block peripheral neuropathic pain development.”
The Ahmed-Wilkerson team hypothesizes that their novel small molecules, which are not related to the tetracycline scaffold, will inhibit EphB1/2 tyrosine kinase signaling.
“These small molecules could prove to be novel tools to investigate the mechanisms that either block or reverse peripheral and central nervous system neuronal activation and nerve damage,” Ahmed said. “This will lead to decreased neuropathic pain-related biomarkers and behaviors associated with peripheral neuropathic pain.”
Related Stories
TTUHSC Researchers Seek Novel Therapies for Chronic Pain
The National Institute of Neurological Disorders and Stroke at the NIH recently awarded a $1.94 million grant to Mahmoud Salama Ahmed, Ph.D., and his project team from the Department of Pharmaceutical Sciences at TTUHSC. Jerry H. Hodge School of Pharmacy.
TTUHSC and TTUHSC El Paso Named to National Academy of Inventors Top 100
For the third consecutive year in a row, the National Academy of Inventors (NAI) ranked the Texas Tech University System (TTU System) among the Top 100 U.S. Universities Granted Utility Patents for 2024. The TTU System, which includes Texas Tech University Health Sciences Center (TTUHSC) and TTUHSC El Paso, ranked 75th.
TTUHSC Recognizes Student Research During Amarillo Research Symposium
More than 100 student and trainee researchers from the Texas Tech University Health Sciences Center (TTUHSC) presented research findings at the 2025 Student Research Day on April 11.
Recent Stories
Measles Outbreak: What to Know From The Future of Health
Kelissa Huse, an assistant professor and laboratory manager in the Molecular Pathology Program at TTUHSC, spoke about measles, the outbreak and what West Texans needs to know about the disease.
Santos Named Department of Surgery Chair for TTUHSC School of Medicine in Lubbock
As the new Department of Surgery chair for the School of Medicine in Lubbock, Ariel Santos, M.D., M.P.H., seeks to elevate TTUHSC’s role as the Hub of Surgery for West Texas.
Covenant Health Brings Kidney Transplant Surgery Back to West Texas
The Kidney Transplant Program at Covenant Medical Center will provide life-changing opportunities for patients suffering from end-stage renal disease (ESRD) and chronic kidney conditions.